[go: up one dir, main page]

PE20240125A1 - Derivados novedosos de pirimidin-2-il sulfonamida - Google Patents

Derivados novedosos de pirimidin-2-il sulfonamida

Info

Publication number
PE20240125A1
PE20240125A1 PE2023002289A PE2023002289A PE20240125A1 PE 20240125 A1 PE20240125 A1 PE 20240125A1 PE 2023002289 A PE2023002289 A PE 2023002289A PE 2023002289 A PE2023002289 A PE 2023002289A PE 20240125 A1 PE20240125 A1 PE 20240125A1
Authority
PE
Peru
Prior art keywords
pyrimidin
sulfonamide
indol
chloro
methoxy
Prior art date
Application number
PE2023002289A
Other languages
English (en)
Inventor
Luca Gobbi
Guido Galley
Wolfgang Guba
Dmitry Mazunin
Emmanuel Pinard
Antonio Ricci
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20240125A1 publication Critical patent/PE20240125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDIN-2-IL SULFONAMIDA DE FORMULA (I) DONDE R1, R2, R3, R4, X1 Y X2 SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: 6-CLORO-N-[5-(2-FLUOROETOXI)-4-METOXI-PIRIMIDIN-2-IL]-1H-INDOL-3-SULFONAMIDA; 6-CLORO-7-FLUOR-N-[5-(2-FLUOROETOXI)-4-METOXI-PIRIMIDIN-2-IL]-1H-INDOL-3-SULFONAMIDA; 6-CLORO-N-[5-(2,2-DIFLUOROETOXI)-4-METOXI-6-METIL-PIRIMIDIN-2-IL]-1H-INDOL-3-SULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DEL RECEPTOR HUERFANO DE CLASE A ACOPLADO A PROTEINAS G 17 (GPR17) SIENDO UTILES EN EL TRATAMIENTO DE MIELINOLISIS CENTRAL PONTINA Y EXTRAPONTINA, DESMIELINIZACION INDUCIDA POR VIRUS, ESCLEROSIS MULTIPLE.
PE2023002289A 2021-02-26 2022-02-24 Derivados novedosos de pirimidin-2-il sulfonamida PE20240125A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21159452 2021-02-26
PCT/EP2022/054586 WO2022180136A1 (en) 2021-02-26 2022-02-24 Novel pyrimidin-2-yl sulfonamide derivatives

Publications (1)

Publication Number Publication Date
PE20240125A1 true PE20240125A1 (es) 2024-01-22

Family

ID=74797733

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002289A PE20240125A1 (es) 2021-02-26 2022-02-24 Derivados novedosos de pirimidin-2-il sulfonamida

Country Status (17)

Country Link
US (1) US20240025883A1 (es)
EP (1) EP4298092B1 (es)
JP (1) JP2024507176A (es)
KR (1) KR20230152006A (es)
CN (1) CN116829550A (es)
AR (1) AR124973A1 (es)
AU (1) AU2022227183A1 (es)
CA (1) CA3203282A1 (es)
CL (1) CL2023002429A1 (es)
CO (1) CO2023010212A2 (es)
CR (1) CR20230410A (es)
IL (1) IL304450A (es)
MX (1) MX2023009045A (es)
PE (1) PE20240125A1 (es)
TW (1) TW202245749A (es)
WO (1) WO2022180136A1 (es)
ZA (1) ZA202305344B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119585258A (zh) * 2022-07-28 2025-03-07 豪夫迈·罗氏有限公司 新颖的7-取代的吲哚磺酰胺衍生物
CA3261059A1 (en) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag NEW INDOLE SULFONAMIDE DERIVATIVES SUBSTITUTED AT POSITION 7
WO2024104462A1 (en) * 2022-11-20 2024-05-23 Myrobalan Therapeutics Nanjing Co. Ltd Gpr17 modulators and uses thereof
CN120530103A (zh) 2023-01-20 2025-08-22 豪夫迈·罗氏有限公司 新颖嘧啶基磺酰胺衍生物
WO2025243044A1 (en) 2024-05-23 2025-11-27 Pheno Therapeutics Limited Compounds
GB202508014D0 (en) 2024-05-23 2025-07-09 Pheno Therapeutics Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
TWI857957B (zh) * 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
EP3584244A1 (en) * 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides

Also Published As

Publication number Publication date
MX2023009045A (es) 2023-08-10
IL304450A (en) 2023-09-01
CL2023002429A1 (es) 2024-01-12
CN116829550A (zh) 2023-09-29
CR20230410A (es) 2023-09-25
ZA202305344B (en) 2024-01-31
EP4298092A1 (en) 2024-01-03
CO2023010212A2 (es) 2023-09-08
AR124973A1 (es) 2023-05-24
CA3203282A1 (en) 2022-09-01
AU2022227183A1 (en) 2023-06-22
JP2024507176A (ja) 2024-02-16
EP4298092B1 (en) 2025-11-26
TW202245749A (zh) 2022-12-01
AU2022227183A9 (en) 2024-10-10
WO2022180136A1 (en) 2022-09-01
KR20230152006A (ko) 2023-11-02
US20240025883A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
PE20240125A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
CR20220371A (es) Agonistas heterocíclicos de glp-1
PE20050867A1 (es) DERIVADOS DE PIPERAZINA COMO INHIBIDORES DE LA INTERACCION DE gp 120 CON CD4
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR037996A1 (es) Compuesto derivado de amino nicotinato, composicion farmaceutica; proceso para su preparacion y su uso como medicamento
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
PE20061148A1 (es) Sal potasica de n-(4-fluorobencil)-5-hidroxi-1-metil-2-(1-metil-1-{[(5-metil-1,3,4-oxadiazol-2-il)carbonil]amino}etil)-6-oxo-1,6-dihidropirimidin-4-carboxamida
PE20081314A1 (es) COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PE20181804A1 (es) Derivados de aminotiazol utiles como agentes antiviricos
PE20140608A1 (es) Analogos de nucleotidos sustituidos
PE20212196A1 (es) Compuestos, composiciones, y metodos para modular la actividad cdk9
PE20181015A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20080421A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
PE20211701A1 (es) Compuestos biciclicos sustituidos como moduladores del receptor farnesoide x
PE20071161A1 (es) Derivados de urea sustituidos como moduladores del sarcomero cardiaco
MX394108B (es) Derivados de indol n-sustituidos.
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones